retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
['breast']
briacell presents positive data demonstrating survival and clinical benefits in advanced metastatic breast cancer at the 2023 aacr #stocksoftheday #stockalert #stocknews #cancer #newclinicaltrialdata 
Find the most important news and press releases about U.S. publicly-traded companies in real-time and stay ahead of the game!